Rodman & Renshaw Maintains NuVasive Market Perform

Rodman & Renshaw maintained its NuVasive NUVA Market Perform rating in a research report published today. In the report, Rodman & Renshaw states, "Street estimates for NuVasive, in our opinion, still remain aggressive and account for substantial operating synergies. NuVasive's business model is highly sensitive to SG&A levels and inherently has a high cost of producing revenues." Shares of NuVasive were trading at $30.38 at the time of posting, down 6.13% from Monday's market close.